The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD

Inonu University0 sites120 target enrollmentJanuary 2003

ConditionsCOPD Acute Exacerbation

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: COPD Acute Exacerbation
Sponsor: Inonu University
Enrollment: 120
Status: Terminated
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study was designed to evaluate the hypothesis that nebulized budesonide) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with acute exacerbations of COPD (AECOPD).

Detailed Description

Patients, hospitalized with AECOPD, were randomized into three groups. Group I received only bronchodilator treatment (BDT), Group II received SC (40 mg prednisolon) plus BDT, and Group III received nebulized budesonide (NB)(1500 mcg qid) plus BDT. Improvement rates in multiple parameters during 10-day hospitalization, and acute exacerbation and re-hospitalization rates within one-month after discharge were compared between the groups.

Registry

clinicaltrials.gov

Start Date

January 2003

End Date

October 2005

Last Updated

20 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Inonu University

Eligibility Criteria

Inclusion Criteria

•COPD patients who were admitted to our pulmonary department for an acute exacerbation were prospectively enrolled in the study

Exclusion Criteria

•COPD patients hospitalized with specific reasons like pneumonia, pulmonary emboli, congestive heart failure, pneumothorax etc. as the cause of acute exacerbation, or patients with risk of imminent respiratory failure requiring mechanical ventilation or direct admission to the ICU were excluded.